Certainly this is not trading down based on the "news" from this morning citing an article from July 2nd about the delay of the Ph. 3 trials.? If so, silly selling if not fully read up on current expected timeline for trials to start in the next week as cited by the company. I saw the analyst report from this morning, but it too is an outlier from the general consensus of PPS- but it even admitted that the MRNA vaccine will likely be approved and was more concerned about price point of vaccine and units sold.
It does not bake in the run that will hopefully be had once a purchase agreement is announced, earnings report in August that will hopefully meet or beat expectations further reducing losses on the balance sheet, and updates about increase production capacity and sales point. Oh, and trial updates to include them kicking it off.
Would like to see close above $80 from chart stand point, but mid term we should do well IMO.
AI
Market Data 
Markets 
